Royce & Associates’s Zymeworks ZYME Stock Holding History

Royce & Associates’s Portfolio ZYME Stock Details ZYME Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-299,202	Closed	-$7.49M	–	846
2026 Q1	$7.49M	Buy	+299,202	New	+$7.08M	0.07%	398

Other funds holding ZYME

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Royce & Associates's ZYME Position: Q2 2026 in Review

Royce & Associates sold out of Zymeworks (ZYME) in Q2 2026, closing a stake of 299,202 shares — an estimated $7.49M sold.

Royce & Associates first reported a position in ZYME in Q1 2026 and held it in 1 quarter. The position peaked at $7.49M in Q1 2026. 203 funds tracked by Wall St. Rank hold ZYME as of Q2 2026.

Royce & Associates reported no remaining Zymeworks position as of Q2 2026 after selling out during the quarter.
Royce & Associates sold 299,202 Zymeworks shares in Q2 2026, an estimated $7.49M.
Royce & Associates first reported a position in Zymeworks in Q1 2026 and held it in 1 quarter.
Royce & Associates's Zymeworks position peaked at $7.49M in Q1 2026.
203 funds tracked by Wall St. Rank held Zymeworks as of Q2 2026.

Based on Royce & Associates's 13F filing for Q2 2026, filed 14 Aug 2026.